ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering
From the ashes of CETP inhibitors emerges obicetrapib, which reduced LDL by 50%, but long-term safety data are still needed.
Source: tctmd.com
Stay updated with breaking news from Anne Tybj. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
From the ashes of CETP inhibitors emerges obicetrapib, which reduced LDL by 50%, but long-term safety data are still needed.